I have seen several posts demanding more detail information
I have seen several posts demanding more detail information from Leo and to those posters I would remind them that there have been 38 PRs in 2020 alone along with several Shareholder Alerts. IPIX also submits quarterly financials with upcoming 12 month budget projections. In the latest 10-Q IPIX projected a 12 month budget projection of $10.3M of which a majority of $8.3M or 80% of the overall budget focused on human clinical trials. If you read the most current PR’s and 10-Q it is pretty obvious that the priority #1 is getting Brilacidin through the upcoming Phase 2 B-CV19 trial followed by priority #2 of getting Brilacidin through Phase 2 B-IBD UC human trials. The major expenses associated with these trials is supplying the drug for the trials and hiring CRO’s to run the trials. The delivery mechanism for B-CV19 is IV based and for B-IBD UC is pill based. These require separate formulations, planning and logistics.
I personally cannot imagine why anyone would make a major investment in a company where they didn’t believe in both the product offering and the company leadership. If I made an error and felt that either the product or management were not capable of success I would sell off my investment and use those funds on something I believed in. I certainly would not waste my time on a message board bad-mouthing a companies’ product or management. I would take it a step further and delete that equity off of my list of stocks to follow.
There is a red flag that goes up for me whenever I see posts that question or try to rationalize why IPIX share price (SP) is depressed. I have to assume that the poster is in one of 2 categories:
1) A very naïve or stubborn investor that cannot comprehend that IPIX SP is COMPLETELY controlled by criminal entities that artificially compress IPIX SP using mirror trades (fake volume) as well as illegal naked short selling (fake shares) on the OTX Market which is NOT a stock exchange. The OTX involves a network of dealers trading stocks directly with each other through Market Makers.
2) A poster that is paid from the criminal entity described above. The criminal organization has a hedge fund towards the top that is the funding source for illegal naked short sales. Below the hedge fund are crooked Market Makers and paid trading gangs. Below them are paid soft bashers and at the bottom of the food chain there are paid hard bashers.
IPIX is about to initiate human trials for the COVID-19 worldwide pandemic where there are no effective therapeutics available. Vaccines are now becoming available but regardless of their effectiveness, there is an extremely strong demand for effective therapeutics. Effective vaccines and effective therapeutics are BOTH needed to save the world from the CV19 pandemic. If Brilacidin works nearly as well in human trials as it did in RBL lab testing then it will be a godsend in treating a virus that has killed over 1.65M people worldwide and over 308k people in the U.S. An effective therapeutic that will save millions of lives and help turn around crippled economies is WORTH MANY BILLIONS IN MARKET CAP. There has never been a higher demand for ANY product or service that I am aware of in my lifetime.
With the high stakes involved it is laughable when some are questioning why $5M was raised to advance IPIX science through this critical Phase 2 B-CV19 human trial. Leo could not be more transparent through multiple PR’s with IPIX’s budget requirements over the coming year with a majority of the overall funding being used for human trials for B-CV19 and for B-IBD UC.
IPIX is still for the time being a pre-revenue biotech. Pre-revenue means that IPIX does not generate revenue. That means that funding is acquired through issuance of stock which in turn requires dilution. The criminal compression of IPIX SP over many years has been successful in forcing IPIX to use very expensive capital via stock issuance at ridiculously compressed prices. The criminals have however NOT been successful in preventing IPIX from advancing Brilacidin to this point in time where it could prove to solve a worldwide need for CV19 therapy.
The Brilacidin human trial for CV19 will start very soon. It may still happen this month or in early January. If it slips into January there will be hundreds of posts that the sky is falling that will demonize Leo and claim that IPIX science is worthless. The criminals will continue to compress IPIX SP as low as they can take it with the only resistance from a few Long Term IPIX investors buying at incredibly low price points. These investors know that the true value of IPIX shares are not what the daily ticker tape shows. The true value of IPIX SP will START to be reflected be once Brilacidin human CV19 trials prove successful which will start a domino effect of events that will take the control of SP AWAY from the criminals. This chain of events include:
- Successful Phase 2 CV19 human trial results
- Grant funding and/ or partnerships for B-CV19
- Emergency and Compassionate Use Approvals
- A funded phase 3 trial that will result in Brilacidin as a fully approved drug
- Worldwide Revenue to IPIX for Brilacidin as the premier therapeutic for CV19
- Advancements of B-IBD UC, B-OM and other Brilacidin uses
- Advancement of Kevetrin
- Up Listing off of the criminally controlled OTX to a legitimate Stock Exchange
- Eventual covering of illegal naked short sales creating an epic short squeeze.
- Additional licensing/ royalties/ partnerships
- Eventual buy out of IPIX from a much larger entity.
As the above dominos (milestones) are achieved, IPIX will attract a flood of new investor demand that will dwarf the minimal amount of legitimate volume that is a subset of current published volume which today is mostly fake. This new investor demand will drive up IPIX SP into multiple dollar ranges versus the current environment of being priced in pennies. The criminals will maintain control of IPIX share price for a couple more months until they start to lose control as good results from the upcoming trial are announced. In the meantime Longs who know what they own will sit tight and possibly nibble on some additional cheap shares. Longs know what we own and are not selling at ridiculously low levels. The criminals can start to pick off a small portion of my personal IPIX position as my GTC's are all set in the several dollar range. The criminal fear-mongering to me demonstrates their desperation and encourages me to continue to raise most of my GTC's into double digits and some into triple digits.
20
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading
Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...
Continue Reading
Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...
Continue Reading
A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
Top 5 Most Recently Viewed Articles
Elis Capital Structure Overview Elis, a prominent player in the services sector, is committed to providing transparency regarding its capital structure. As of the recent assessment, the company detailed the number of shares that constitute its capital along with the total number of voting rights. Share Capital and Voting Rights According to French legal requirements,...
Continue Reading
A. Walker & Company Secures Major Capital Commitments A. Walker & Co. recently secured a significant capital commitment totaling up to $75 million, including an initial $50 million specifically set aside for affordable housing development. This funding is a critical step towards increasing the availability of multifamily housing that can effectively serve the needs of...
Continue Reading
ClorDiSys Expands Sterilization Operations ClorDiSys Solutions, LLC has announced a significant expansion in its sterilization facilities, designed to address the growing demand for its chlorine dioxide-based sterilization services. This expansion includes the addition of new chambers, which will effectively double the company’s processing capacity. With the new...
Continue Reading
KBS Builders Secures Significant Commercial Contracts Star Equity Holdings, Inc. is excited to announce that its subsidiary, KBS Builders, has successfully signed two major contracts worth a total of $5.2 million. These contracts focus on the manufacturing of housing units, promising to contribute positively not only to KBS's growth but also to addressing the ongoing...
Continue Reading
Understanding the Existing Market Trap A fresh approach from the creators of Play Bigger reveals the hidden costs startups face. The new book titled The Existing Market Trap: A Primer presents a timely exploration into why many startups struggle to gain traction. Co-authors Al Ramadan, Christopher Lochhead, alongside new contributors Jason Wellcome and Mary Gr
Continue Reading